tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD) and Beam Therapeutics (BEAM)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ACADIA Pharmaceuticals (ACADResearch Report) and Beam Therapeutics (BEAMResearch Report).

ACADIA Pharmaceuticals (ACAD)

In a report issued on February 28, Gregory Renza from RBC Capital maintained a Buy rating on ACADIA Pharmaceuticals, with a price target of $34.00. The company’s shares closed last Tuesday at $25.07.

According to TipRanks.com, Renza is a 1-star analyst with an average return of -2.8% and a 38.3% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Prometheus Biosciences, and Pacira Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $29.53 average price target, implying a 21.8% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $36.00 price target.

See today’s best-performing stocks on TipRanks >>

Beam Therapeutics (BEAM)

RBC Capital analyst Luca Issi maintained a Hold rating on Beam Therapeutics on February 28 and set a price target of $85.00. The company’s shares closed last Tuesday at $73.50.

According to TipRanks.com, Issi has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -24.1% and a 28.6% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Crispr Therapeutics AG, and Ionis Pharmaceuticals.

Currently, the analyst consensus on Beam Therapeutics is a Strong Buy with an average price target of $126.25, which is a 62.3% upside from current levels. In a report issued on February 28, J.P. Morgan also maintained a Hold rating on the stock with a $110.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ACAD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed